ProSciento: financing from 1315
ProSciento, a specialty clinical research organization focused on metabolic diseases, has closed on growth financing from healthcare investment outfit 1315 Capital. The funds reportedly will support expansion of the company’s CRO operations and patient-access platforms.
“ProSciento has established an outstanding reputation as the leading provider of early stage clinical research services for metabolic diseases,” said Matthew Reber, partner at 1315 Capital. “Our firm seeks to make a positive impact on patients and the entire healthcare system, and ProSciento is a key addition to the portfolio.”